GLA
NVO

Good Life Advisors’s Novo Nordisk NVO Stock Holding History

Good Life Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,340
Closed -$201K – 513
2024
Q4 		$201K Sell
2,340
-26,315
-92% -$2.85M 0.01% 463
2024
Q3 		$3.41M Buy
28,655
+2,293
+9% +$306K 0.21% 96
2024
Q2 		$3.76M Buy
26,362
+2,395
+10% +$317K 0.31% 64
2024
Q1 		$3.08M Buy
23,967
+1,492
+7% +$178K 0.27% 72
2023
Q4 		$2.33M Buy
+22,475
New +$2.22M 0.23% 85

Other funds holding NVO

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Good Life Advisors's NVO Position: Q1 2025 in Review

Good Life Advisors sold out of Novo Nordisk (NVO) in Q1 2025, closing a stake of 2,340 shares — an estimated $201K sold.

Good Life Advisors first reported a position in NVO in Q4 2023 and held it in 5 quarters. The position peaked at $3.76M in Q2 2024. 1,530 funds tracked by Wall St. Rank hold NVO as of Q1 2025.

  • Good Life Advisors reported no remaining Novo Nordisk position as of Q1 2025 after selling out during the quarter.
  • Good Life Advisors sold 2,340 Novo Nordisk shares in Q1 2025, an estimated $201K.
  • Good Life Advisors first reported a position in Novo Nordisk in Q4 2023 and held it in 5 quarters.
  • Good Life Advisors's Novo Nordisk position peaked at $3.76M in Q2 2024.
  • 1,530 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2025.

Based on Good Life Advisors's 13F filing for Q1 2025, filed 17 Apr 2025.